EU Authorizes ImmunityBio’s ANKTIVA, Expanding Global Commercial Reach

ImmunityBio expands global commercial reach after EU authorization

ImmunityBio is rapidly expanding its international commercial footprint after the European Commission grants authorization for its cancer vaccine ANKTIVA, the company is capitalizing on regulatory momentum that now spans four jurisdictions in less than two years since its initial U.S. approval. The EC decision comes alongside prior approvals in the Kingdom of Saudi Arabia, where ANKTIVA holds authorization for two indications, and signals regulatory acceptance across strategically important markets. Company executives are using the approvals to accelerate market entry plans, broaden distribution channels and pursue local procurement and reimbursement discussions.

The multi-jurisdictional approvals strengthen ImmunityBio’s ability to scale manufacturing and collect real-world evidence, the company is positioning ANKTIVA for wider clinical adoption while preparing post-approval studies that could support further label expansions. Rapid authorization across diverse healthcare systems shortens timelines to patient access and increases opportunities for commercial partnerships and national tenders, particularly in regions where oncology vaccine adoption is nascent. ImmunityBio is also focusing on supply‑chain resilience and physician education to support uptake as it moves beyond a U.S.-centric commercialization strategy.

Regulatory progress in Europe and Saudi Arabia also underpins ImmunityBio’s argument for ANKTIVA’s commercial viability and may facilitate negotiations with payers and hospital systems, the company is citing the approvals to bolster market-access discussions and to build a platform for additional regulatory filings and real‑world data collection. Taken together, the approvals mark a decisive step in shifting ImmunityBio from a single-market approval to a coordinated international rollout that the company expects will expand its addressable patient population and support long‑term growth initiatives.

Broader oncology innovation accelerates

The regulatory activity comes as the oncology field sees rapid innovation: more than 2,100 oncology clinical trials start globally in 2024, with targeted therapies the fastest‑growing subsegment and over 100 antibody‑drug conjugates now in active development. Leading researchers at AACR forecast that by 2026 smarter delivery systems — armored T cells, off‑the‑shelf NK platforms and radiopharmaceuticals targeting stromal and receptor biology — will see wider deployment.

Peer advances highlight the competitive and regulatory backdrop, notably Oncolytics Biotech’s recent FDA Fast Track designation for pelareorep in second‑line KRAS‑mutant, microsatellite‑stable metastatic colorectal cancer. That designation rests on data showing a 33% objective response rate and median overall survival of 27.0 months versus 11.2 months for standard therapy, underscoring how emergent modalities are producing registration‑enabling signals in historically resistant tumors.